SOURCE: Cardio3

June 07, 2007 09:15 ET

Cardio3 BioSciences Licenses Cardiac Stem Cell Technology From Mayo Clinic

"This Exceptional Opportunity Positions Cardio3 BioSciences as a Global Leader in the Field of Regenerative Therapies for Heart Failure." - Christian Homsy, MD, CEO, Cardio3 BioSciences

BRAINE L'ALLEUD, BELGIUM and ROCHESTER, MN--(Marketwire - June 7, 2007) - Cardio3 BioSciences ( and Mayo Clinic announced today that they have entered into a collaborative agreement related to the licensing of Mayo Clinic research, know-how and intellectual property in the field of cardiac commitment of stem cells.

The research, headed by Prof. André Terzic and Dr. Atta Behfar at Mayo Clinic, has focused on the guided commitment of adult as well as embryonic stem cells. The scope of the license covers heart failure of ischemic and non-ischemic origin.

"This opportunity positions Cardio3 BioSciences as a global leader in the field of regenerative therapies for heart failure," said Christian Homsy, MD, CEO of Cardio3 BioSciences. "The agreement includes existing intellectual property and a commitment to ongoing collaborative research projects in early-development stages at Mayo Clinic."

"Over one million Americans suffer a new or recurrent heart attack each year. Despite the aggressive approaches we use to treat heart patients, no effective means are available to repair a damaged heart," added André Terzic, MD, PhD, Mayo Clinic. "Discoveries by the Mayo team open new therapeutic avenues exploiting the regenerative potential of stem cells guided toward cardiac lineage. We are excited about translating this novel methodology into repair strategies."

"Research performed at Mayo Clinic has led to a number of high-level publications in peer-reviewed journals. The results obtained by the Mayo research team are very promising, and will allow Cardio3 BioSciences to enter immediately into the last phase of preclinical work, with the goal of performing a first human procedure as early as Q2 2008," concluded Dr. Homsy.

Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. More than 2,500 physicians and scientists and 42,000 allied health staff work at Mayo Clinic, which has sites in Rochester, Minn., Jacksonville, Fla., and Scottsdale/Phoenix, Ariz. Collectively, the three locations treat more than half a million people each year.

Cardio3 BioSciences is a Belgian start-up company active in the field of cardiac commitment of stem cells.

Contact Information

  • Contact:
    Ronald Trahan, APR
    Ronald Trahan Associates Inc.
    508-359-4005, x108